The evolution of treatment resistance: biologic implications.

Abstract:

:The evolution of resistance of positive symptoms to antipsychotic therapy may represent a valuable means of subtyping schizophrenia. In contrast, resistance of negative symptoms and cognitive function to antipsychotic agents seems to be present from the first episode of psychotic symptoms and does not evolve over time to the same extent. If these findings are validated, this clearly points toward differences in the etiology of these components of schizophrenia. Data from a cohort of 223 patients with unsatisfactory responses to classical antipsychotic therapy are evaluated, at least 60% of whom responded to subsequent treatment with clozapine. Comparisons were made between the subgroups of patients with primary and delayed onset treatment resistance. Both subgroups responded to clozapine therapy, although better response was evident for patients with delayed resistance. The withdrawal of clozapine from patients who had previously been responsive to classical antipsychotic therapy was capable of inducing treatment resistance.

journal_name

J Clin Psychopharmacol

authors

Meltzer HY,Lee M,Cola P

doi

10.1097/00004714-199804001-00003

subject

Has Abstract

pub_date

1998-04-01 00:00:00

pages

5S-11S

issue

2 Suppl 1

eissn

0271-0749

issn

1533-712X

journal_volume

18

pub_type

杂志文章,评审
  • Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation: A Retrospective Cohort Study.

    abstract:PURPOSE:Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate. METHODS:In a retrospective cohort study extending over 6 years, all patients admitted for inpatient treatment with a diagn...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000672

    authors: Rittmannsberger H,Rosenleitner J,Malsiner-Walli G,Werl R,Rittmannsberger B,Yazdi K

    更新日期:2017-04-01 00:00:00

  • Effect of citalopram treatment on relationship between platelet serotonin functions and the Karolinska scales of personality in panic patients.

    abstract::Using the Karolinska Scales of Personality (KSP), we investigated the effect of the selective serotonin reuptake inhibitor citalopram on personality traits and the relationship between personality traits and peripheral indexes for central serotonergic function in patients with panic disorder at baseline and after 6 mo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200208000-00011

    authors: Neuger J,Wistedt B,Aberg-Wistedt A,Stain-Malmgren R

    更新日期:2002-08-01 00:00:00

  • Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

    abstract::Adverse events during selective serotonin reuptake inhibitor (SSRI) treatment are frequent and may lead to premature treatment discontinuation. If attrition is associated with early worsening of adverse effects or the frequency, intensity, or burden of adverse effects, interventions to maximize retention could be focu...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/JCP.0b013e3181dbfd04

    authors: Warden D,Trivedi MH,Wisniewski SR,Kurian B,Zisook S,Kornstein SG,Friedman ES,Miyahara S,Leuchter AF,Fava M,Rush AJ

    更新日期:2010-06-01 00:00:00

  • Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.

    abstract::Dextromethorphan is a nonopioid antitussive metabolized by cytochrome P450 2D6 (CYP2D6) to an active metabolite, dextrorphan. CYP2D6 is polymorphically expressed in humans, with 5 to 10% of Caucasians being homozygous deficient for the active form of the enzyme. In a pilot study, the authors investigated the pharmacol...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199808000-00014

    authors: Zawertailo LA,Kaplan HL,Busto UE,Tyndale RF,Sellers EM

    更新日期:1998-08-01 00:00:00

  • The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.

    abstract:BACKGROUND:The combination of olanzapine and valproic acid (VPA) is regularly prescribed in the treatment of bipolar or schizoaffective disorders. The VPA has been shown to reduce olanzapine concentration, but the mechanism behind this interaction remains unknown. We aimed to investigate the effect of VPA on olanzapine...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001126

    authors: Tveito M,Smith RL,Høiseth G,Molden E

    更新日期:2019-11-01 00:00:00

  • Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

    abstract:BACKGROUND:Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluati...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000766

    authors: Foster A,Buckley P,Lauriello J,Looney S,Schooler N

    更新日期:2017-10-01 00:00:00

  • Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.

    abstract:OBJECTIVE:Pharmacogenetic studies on clozapine (CLZ) have provided meaningful insights but have shown redundancies owing to wide interindividual variability and insufficient replication. The present study was designed to validate hitherto suggested candidate genes on CLZ pharmacokinetics and pharmacodynamics and explor...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31825ac35c

    authors: Lee ST,Ryu S,Kim SR,Kim MJ,Kim S,Kim JW,Lee SY,Hong KS

    更新日期:2012-08-01 00:00:00

  • Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.

    abstract:PURPOSE/BACKGROUND:The purpose of this study was to examine the relationships between ytochrome P450 family 2 subfamily C member 19 (CYP2C19) polymorphisms, brain-derived neurotrophic factor (BDNF) plasma levels, and treatment responses to escitalopram in Chinese patients with panic disorder (PD). METHODS/PROCEDURES:N...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001014

    authors: He Q,Mei Y,Liu Y,Yuan Z,Zhang J,Yan H,Shen L,Zhang Y

    更新日期:2019-03-01 00:00:00

  • Nifedipine in the treatment of tardive dyskinesia.

    abstract::There have been several case reports of improvement in tardive dyskinesia (TD) after treatment with calcium-blocking agents. We have conducted prior single-blind (rater-blind) studies of verapamil and diltiazem and found a statistically significant improvement in TD with verapamil, and a small improvement that did not...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199010060-00006

    authors: Duncan E,Adler L,Angrist B,Rotrosen J

    更新日期:1990-12-01 00:00:00

  • Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

    abstract:CONTEXT:Major depressive disorder causes significant morbidity and mortality. Current therapies fail to fully treat both emotional and physical symptoms of major depressive disorder. OBJECTIVE:To evaluate duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on improvement of emotional and painful phy...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.jcp.0000132448.65972.d9

    authors: Goldstein DJ,Lu Y,Detke MJ,Wiltse C,Mallinckrodt C,Demitrack MA

    更新日期:2004-08-01 00:00:00

  • St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study.

    abstract::Recognition of social anxiety disorder (social phobia) as a common and disabling condition has led to new advances in its pharmacotherapy. Limitations with selective seroton reuptake inhibitors (side effects) and behavior therapy (scarcity of trained therapists), coupled with the tendency for patients with the disorde...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000150227.61501.00

    authors: Kobak KA,Taylor LV,Warner G,Futterer R

    更新日期:2005-02-01 00:00:00

  • Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.

    abstract::We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year. Blood samples were obtained after an 11-hour (+/...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000227705.56870.06

    authors: Hardy TA,Marquez E,Kryzhanovskaya L,Taylor CC,Cavazzoni P

    更新日期:2006-08-01 00:00:00

  • Unaltered Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia After 6 Months of Antipsychotics Treatment: A Naturalistic Study.

    abstract:BACKGROUND:Dopaminergic dysfunction, namely, dopamine transporter (DAT) availability variations in patients with drug-naive schizophrenia after long-term treatment, is still not well understood. The aims of the study were to explore (i) whether the DAT availability in patients with drug-naive schizophrenia differed aft...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000632

    authors: Chang WH,Chen KC,Lee IH,Chi MH,Chen PS,Yao WJ,Chiu NT,Yang YK

    更新日期:2017-02-01 00:00:00

  • Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial.

    abstract::Sexual dysfunctions (SDs) occur frequently in schizophrenia patients and have a huge impact on quality of life and compliance. They are often associated with antipsychotic medication. Nicotine consumption, negative or depressive symptoms, and physical illness are also discussed as contributing factors. Data on SD in f...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e3182199bcc

    authors: Malik P,Kemmler G,Hummer M,Riecher-Roessler A,Kahn RS,Fleischhacker WW,EUFEST Study Group.

    更新日期:2011-06-01 00:00:00

  • Open-label pilot study of modafinil for methamphetamine dependence.

    abstract::Methamphetamine has become a major public health issue globally, particularly in the United States. Despite this, no effective pharmacotherapy for methamphetamine abuse has been developed to date. This 6-week, open-label pilot clinical trial examined the safety and tolerability of modafinil up to 400 mg/d in 8 methamp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3181b591e0

    authors: McGaugh J,Mancino MJ,Feldman Z,Chopra MP,Gentry WB,Cargile C,Oliveto A

    更新日期:2009-10-01 00:00:00

  • Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia.

    abstract::Disordered water balance, or polydipsia, is an underassessed and underreported phenomenon present in the severely psychiatrically disabled population. Prevalence rates for polydipsia range from 6.2 to 20%. We followed up five male patients (mean age 43) with chronic schizophrenia who met the Kane criteria for being tr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199608000-00010

    authors: Fuller MA,Jurjus G,Kwon K,Konicki PE,Jaskiw GE

    更新日期:1996-08-01 00:00:00

  • Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

    abstract::The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with symptomatic SCA. Subje...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000535

    authors: Fu DJ,Turkoz I,Simonson RB,Walling D,Schooler N,Lindenmayer JP,Canuso C,Alphs L

    更新日期:2016-08-01 00:00:00

  • Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia.

    abstract::The pharmacokinetic parameters of clozapine and its two main metabolites, N-desmethylclozapine (norclozapine, active metabolite) and clozapine N-oxide, were evaluated, after oral administration, in 19 patients with chronic schizophrenia. Plasma and red blood cell (RBC) drug concentrations were determined by high-perfo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199812000-00010

    authors: Guitton C,Abbar M,Kinowski JM,Chabrand P,Bressolle F

    更新日期:1998-12-01 00:00:00

  • Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials.

    abstract::Depression in the elderly patient may present special challenges for the design of clinical treatment trials due to a complex antidepressant treatment history, individual contraindications to certain medications, medical comorbidity, as well as concurrent medications for other medical conditions. The chronic, relapsin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.jcp.0000168502.16361.ad

    authors: Lavori PW

    更新日期:2005-08-01 00:00:00

  • Tiaspirone in schizophrenia.

    abstract::It was predicted that tiaspirone, a novel compound, would benefit schizophrenic patients since in animal experiments it is a potent dopamine blocker. Following a placebo washout period of 1 to 2 weeks, 14 patients were treated for 28 days with the drug in a single-blind, dose ranging trial. GAS, NOSIE, and BPRS scores...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Moore NC,Meyendorff E,Yeragani V,LeWitt PA,Gershon S

    更新日期:1987-04-01 00:00:00

  • Predictors for starting depot administration of risperidone in chronic users of antipsychotics.

    abstract:BACKGROUND:Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparison...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31818a6d10

    authors: Vehof J,Postma MJ,Bruggeman R,De Jong-Van Den Berg LT,Van Den Berg PB,Stolk RP,Burger H

    更新日期:2008-12-01 00:00:00

  • Molindone hydrochloride: a review of laboratory and clinical findings.

    abstract::Molindone hydrochloride, a dihydroindolone neuroleptic, is structurally distinct from other classes of neuroleptics. Molindone exhibits many similarities to other neuroleptics, including dopamine receptor blockade, antipsychotic efficacy, and extrapyramidal side effects. Despite these similarities, molindone also has ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Owen RR Jr,Cole JO

    更新日期:1989-08-01 00:00:00

  • Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures.

    abstract::The clinical features and pharmacokinetics of 22 lithium overdoses are described. Effectiveness of different treatment regimens regarding elimination of lithium is discussed. Origin of overdose was due to deliberate poisoning or precipitated by concomitant diseases, coadministration of drugs, or combination of both. T...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000218405.02738.b3

    authors: Eyer F,Pfab R,Felgenhauer N,Lutz J,Heemann U,Steimer W,Zondler S,Fichtl B,Zilker T

    更新日期:2006-06-01 00:00:00

  • Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.

    abstract::We examined kinetic and dynamic factors to determine the pharmacological and behavioral safety and tolerability of low versus high doses of an opiate antagonist, naltrexone (50 mg/day vs. 100 mg/day), and acamprosate (2 g/day vs. 3 g/day), a functional N-methyl-D-aspartate receptor antagonist, both independently and c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000084029.22282.bb

    authors: Johnson BA,O'Malley SS,Ciraulo DA,Roache JD,Chambers RA,Sarid-Segal O,Couper D

    更新日期:2003-06-01 00:00:00

  • Alprazolam kinetics in patients with renal insufficiency.

    abstract::Alprazolam kinetics following a single 1.0-mg oral dose of alprazolam were compared between seven dialysis-dependent patients with chronic renal failure and seven healthy controls matched for age, sex, and weight. There were no significant differences between patients and controls in alprazolam half-life (11.5 vs. 11....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Ochs HR,Greenblatt DJ,Labedzki L,Smith RB

    更新日期:1986-10-01 00:00:00

  • Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.

    abstract:OBJECTIVE:This prospective study sought to compare the acute effects of haloperidol, amisulpride, and quetiapine on serum markers of bone formation and resorption in relatively young patients with minimal previous exposure to antipsychotic drugs. METHODS:Patients included in the study were randomly assigned to receive...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000379

    authors: Liang Y,Su YA,Zhao ZG,Gao N,Huang JZ,Tang MQ,Li KQ,Yang FD,Yu X,Si TM

    更新日期:2015-10-01 00:00:00

  • Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.

    abstract::Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged. At the time of follow-up, half of the patients were medication free, e...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nagy LM,Krystal JH,Charney DS,Merikangas KR,Woods SW

    更新日期:1993-02-01 00:00:00

  • A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response.

    abstract::Although a relatively common behavior, treatment data for pathological skin picking (PSP) are limited. The current study sought to examine the efficacy and tolerability of lamotrigine in adults with PSP and to examine neurocognitive predictors of treatment response. Thirty-two subjects (29 female subjects [90.6%]; mea...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3181e617a1

    authors: Grant JE,Odlaug BL,Chamberlain SR,Kim SW

    更新日期:2010-08-01 00:00:00

  • Clinical safety of flurazepam and midazolam during 14-day use in chronic insomniacs.

    abstract::Data from evening questionnaires, reports of side effects, laboratory findings, and all-night respiratory measurements were collected on the 99 chronic insomniacs examined in this multicenter study. These data were used to compare the clinical safety and desirability of a benzodiazepine hypnotic with a very short half...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Sateia MJ,Hauri P,Kripke D,Roehrs T

    更新日期:1990-08-01 00:00:00

  • Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.

    abstract::In an open clinical trial, serum concentrations of haloperidol pyridinium (C(HP+)) and reduced haloperidol pyridinium (C(RHP+)), as well as haloperidol (CH) and reduced haloperidol (C(RH)), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was moni...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200004000-00014

    authors: Ulrich S,Neuhof S,Braun V,Danos P,Pester U,Hoy L

    更新日期:2000-04-01 00:00:00